Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 4NIH 3INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 3

Conditions

Neoplasms 7Multiple Myeloma 7Lymphoma 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, T-Cell, Cutaneous 4Mycosis Fungoides 3Sezary Syndrome 2Recurrence 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Immunoproliferative Disorders 2Immune System Diseases 2Vascular Diseases 1Stage IIIB or IV Non-Small Cell Lung Cancer 1Paraproteinemias 1Pancreatic Neoplasms 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia 1

Interventions

hypericin 4zanolimumab 3mogamulizumab 3cobomarsen 3Vorinostat 3Bexarotene 3denileukin diftitox 2Vitamin B 12 2Panobinostat 2Folic Acid 2Amines 2A-dmDT390-bisFv(UCHT1) protein 210-propargyl-10-deazaaminopterin 2talimogene laherparepvec 1resminostat 1ontuxizumab 1navitoclax 1forodesine 1TTI-621 1Radiation 1N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide 1Methotrexate 1Mechlorethamine 1MAC-ST-001 1Interleukin-12 Subunit p35 1Fentanyl 1Fenretinide 1Duration of Therapy 1Drug Therapy 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Mycosis Fungoides × Vorinostat × Clear all
NCT02943642 2026-05-18

Resimmune®

Virogen Biotechnology Inc.

Phase 2 Withdrawn
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT03713320 2022-04-08

SOLAR

miRagen Therapeutics, Inc.

Phase 2 Terminated
37 enrolled 23 charts
DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00091559 2017-04-05

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Merck Sharp & Dohme LLC

Phase 2 Completed
74 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡